ERBB2 and B-cell non-Hodgkin lymphoma: Humanized monoclonal antibodies (mAbs) like rituximab and trastuzumab, which are employed for treatment of B cell lymphoma and Her2/neu-positive breast cancer, respectively, have considerably improved therapeutic options for these diseases and are nowadays well established in cancer treatment.